Novel Findings in Pediatric and Adolescent Patients With Cancer and a Germline SMARCA4 Variant
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.31872 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Nienke van Engelen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: DNA Helicases, Nuclear Proteins, Transcription Factors, Germ-Line Mutation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Stichting Kinderen Kankervrij.
Abstract (Originalsprache)
Introduction
SMARCA4 is a known susceptibility gene for malignant rhabdoid tumors (MRT) in children and small cell carcinoma of the ovary hypercalcemic type (SCCOHT) in young females and women. Recently, a novel association between germline SMARCA4 variants and predisposition to neuroblastoma was proposed.
Methods
We present a single‐center study summarizing the clinical and genetic data of pediatric and adolescent cancer patients with a germline SMARCA4 variant diagnosed with and/or treated for an MRT, SCCOHT, or neuroblastoma.
Results
We identified nine patients with germline SMARCA4 variants, including one patient with an MRT, four patients with a SCCOHT, and four patients with a neuroblastoma. We observed two novel pathogenic SMARCA4 variants that were initially missed using diagnostic testing: a low‐mosaic pathogenic SMARCA4 variant in the patient with an MRT, and a germline SMARCA4 partial gene deletion, encompassing the promoter region, in a patient with a SCCOHT. The patients with neuroblastoma in our cohort had a strikingly old age at diagnosis (range: 10–22 years old). In three of four patients with neuroblastoma, the germline SMARCA4 variant was a variant of unknown significance (VUS). In two of their neuroblastomas, we observed loss of heterozygosity at the SMARCA4 locus, and loss of BRG1 expression was found in one of these.
Conclusions
This study highlights that awareness is needed for easy‐to‐miss germline variants in SMARCA4 and that knowledge about variant types, cancer spectrum, and cancer penetrance in individuals with a germline SMARCA4 variant is still evolving.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
- Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
- Department of Genetics, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
- Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
- Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University Medical Center, Utrecht, The Netherlands.
- Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
ORCID-Profile: Nienke van Engelen, Seok-Young Kim
Förderung
- Stichting Kinderen Kankervrij
Zitieren
APA
van Engelen, N., de Krijger, R. R., Kleisman, M. M., Kester, L. A., Hopman, S. M. J., Kranendonk, M. E. G., Vermeulen, M. A., Tops, C., Kim, S. Y., Clevers, H., Neveling, K., Kuiper, R. P., & Jongmans, M. C. J. (2025). Novel Findings in Pediatric and Adolescent Patients With Cancer and a Germline SMARCA4 Variant. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31872
Vancouver
van Engelen N, de Krijger RR, Kleisman MM, Kester LA, Hopman SMJ, Kranendonk MEG, et al. Novel Findings in Pediatric and Adolescent Patients With Cancer and a Germline SMARCA4 Variant. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31872
BibTeX
@article{vanEngelen2025,
author = {van Engelen, Nienke and de Krijger, Ronald R and Kleisman, Michelle M and Kester, Lennart A and Hopman, Saskia M J and Kranendonk, Mariette E G and Vermeulen, Marijn A and Tops, Carli and Kim, Seok-Young and Clevers, Hans and Neveling, Kornelia and Kuiper, Roland P and Jongmans, Marjolijn C J},
title = {Novel Findings in Pediatric and Adolescent Patients With Cancer and a Germline SMARCA4 Variant},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.31872}
}
EUVIMED